Radiopharmaceutical developer Agenix is highlighting the results of a new clinical study on the safety of its ThromboView SPECT radiopharmaceutical for detecting pulmonary embolism (PE).
ThromboView is a technetium-99m-based radiopharmaceutical developed to test for pulmonary embolism and other forms of thrombosis. Results from the 16-patient multicenter prospective phase IB study are scheduled for publication in a future issue of Heart, Lung, and Circulation, according to the firm.
The study concluded that ThromboView "is well-tolerated in patients with acute PE and does not induce an immune response. [ThromboView] may offer a novel approach to imaging PE in a clinically acceptable time frame without exposure to potentially nephrotoxic radiographic contrast agents."
